Baxter International has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction, which includes manufacturing operations from Ipsen Pharma, is subject to regulatory approvals.   Baxter will make an upfront payment of $50 million and may make payments of as much as $20 million based on regulatory approval in the U.S. and its first additional country. A...